logo
logo

Qnovia, Inc. Raises $17 Million In Series A Funding To Advance Its Inhalable Therapeutics Pipeline

Sep 28, 2022•almost 3 years ago

Amount Raised

$17 Million

Round Type

series a

RichmondTherapeuticsPharmaceuticalMedicalBiotechnologyHealth Care

Description

Qnovia, Inc. (Qnovia), a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases, today announced it has raised $17 million in Series A funding. The financing was led by Blue Ledge Capital and included DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures.

Company Information

Company

Qnovia

Location

2920 WEST BROAD ST.

Richmond, Virginia, United States

About

Qnovia was formerly known as Respira Technologies. Qnovia, Inc. is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. The company’s drug delivery platform, the RespiRx™, is the first orientation-agnostic, portable vibrating mesh nebulizer that effectively operates in any position held by the patient. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs. The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People